Investing Center Preview – Manage your investments and watch your net worth grow.
BIIB:NASDAQ – Large Cap Stock (Drug Manufacturers)
Biogen Inc – BIIB Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
122.98 | -7.73 (-5.91%) | 122.77 - 238.00 | 3.1 million (Above Avg) |
Market data as of 4:00PM 04/04/25. Quotes are delayed by at least 15 min.
Overview - BIIB
Open | 129.22 |
---|---|
Previous Close | 130.71 |
Day's Range | 122.77 - 129.95 |
Market Cap | 18.0B |
Avg Volume (10 Day) | 1.8M |
Price/Earnings (Trailing 12 Mo.) | 11.7x |
Earnings Per Share (Trailing 12 Mo.) | 5.042 |
Dividend Yield | No Dividend |
One-Click Scorecard - BIIB


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Pass |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Pass |
Increased shareholder value? | Pass |
Consistently increased owner earnings? | Fail |
Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Neutral |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Fail |
Stock is undervalued? | Pass |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - BIIB
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
Business Wire - Tuesday 04/01/2025 7:30 AM ET
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
Business Wire - Thursday 03/20/2025 8:00 AM ET
Industry Position - BIIB
BIIB | Industry Range | |
---|---|---|
Revenue Growth (1yr) | -1.62% | |
Net Income Growth (1yr) | 40.57% | |
Total Debt/Equity | 0.40 | |
LT Debt/Equity | 0.29 | |
Earnings Yield | 8.55% | |
Price/Sales | 1.97 |